Discovery of a first-in-class ANXA3 degrader for the treatment of triple-negative breast cancer.
10.1016/j.apsb.2022.11.023
- Author:
Yongxi LIANG
1
;
Delin MIN
1
;
Hulin FAN
1
;
Kunlin LIU
1
;
Juchuanli TU
2
;
Xueyan HE
2
;
Bingjie LIU
2
;
Lu ZHOU
1
;
Suling LIU
2
;
Xun SUN
1
Author Information
1. School of Pharmacy, Fudan University, Shanghai 201203, China.
2. Fudan University Shanghai Cancer Center & Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering, Fudan University, Shanghai 200032, China.
- Publication Type:Journal Article
- Keywords:
Annexin A3 (ANXA3);
Degrader;
Patient-derived xenograft;
Triple-negative breast cancer;
Ubiquitination
- From:
Acta Pharmaceutica Sinica B
2023;13(4):1686-1698
- CountryChina
- Language:English
-
Abstract:
Triple-negative breast cancer (TNBC) is a nasty disease with extremely high malignancy and poor prognosis. Annexin A3 (ANXA3) is a potential prognosis biomarker, displaying an excellent correlation of ANXA3 overexpression with patients' poor prognosis. Silencing the expression of ANXA3 effectively inhibits the proliferation and metastasis of TNBC, suggesting that ANXA3 can be a promising therapeutic target to treat TNBC. Herein, we report a first-in-class ANXA3-targeted small molecule (R)-SL18, which demonstrated excellent anti-proliferative and anti-invasive activities to TNBC cells. (R)-SL18 directly bound to ANXA3 and increased its ubiquitination, thereby inducing ANXA3 degradation with moderate family selectivity. Importantly, (R)-SL18 showed a safe and effective therapeutic potency in a high ANXA3-expressing TNBC patient-derived xenograft model. Furthermore, (R)-SL18 could reduce the β-catenin level, and accordingly inhibit the Wnt/β-catenin signaling pathway in TNBC cells. Collectively, our data suggested that targeting degradation of ANXA3 by (R)-SL18 possesses the potential to treat TNBC.
